Table 2.
Safety parameters, clinical, and angiographic outcome
| Group 1: IVT (n = 81) | Group 2: IVT + mTE/aTE (n = 122) | Group 3: mTE/aTE (n = 226) | p value* 1 vs. 2 OR 95% CI | p value* 1 vs. 3 OR 95% CI | |
|---|---|---|---|---|---|
| PH, % | 5.8 | 5.7 | 6.3 | 1 | 1 |
| SICH, % | 2.5 | 3.3 | 1.3 | 1 | 0.610 |
| SAH, % | 7.4 | 9.8 | 9.5 | 0.792 | 0.809 |
| mRS at 90 days, % | |||||
| mRS ≤2 | 61.7 | 32.2 | 34.5 | <0.001 | <0.001 |
| mRS >2 | 38.3 | 67.8 | 65.5 | 3.39 (1.83–6.28) | 3.06 (1.78–5.27) |
| Mortality at 90 days, n (%) | 8 (9.9) | 25 (20.7) | 66 (29.6) | 0.052 | <0.001 |
| mTICI final, n (%) | 0.252 | 0.656 | |||
| 0–2a | 6 (7.4) | 16 (13.1) | 22 (9.7) | ||
| 2b, 3 | 75 (92.6) | 106 (86.9) | 204 (90.3) | ||
| mTICI final 3, n (%) | 15 (18.5) | 74 (60.7) | 129 (57.1) | <0.001 | <0.001 |
* Fisher's exact test.
IVT, intravenous thrombolysis; mRS, modified Rankin Scale; mTE/aTE, aspiration and mechanic thrombectomy; mTICI, modified treatment in cerebral ischemia; PH, parenchymal hemorrhage; SAH, subarachnoid hemorrhage; SICH, symptomatic intracranial hemorrhage.